Paula Crowley
About Paula Crowley
Paula Crowley, age 70, is an independent director of Global Medical REIT Inc. (GMRE) and has served on the Board since June 2018. She co‑founded Anchor Health Properties in 1987, serving as CEO until October 2015, later as Chairman (Oct 2015–Nov 2017) and Chair Emeritus since November 2017; her background is in healthcare real estate and urban retail development (Rouse Company). She holds a BA from Middlebury College, a Master’s in City Planning from the University of Pennsylvania, and an MBA from the Wharton School. The Board has determined she is independent under SEC Rule 10A‑3 and NYSE standards, and her financial expertise qualifies her to serve on the Audit Committee .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Anchor Health Properties | Co‑founder; Chief Executive Officer | 1987–Oct 2015 | National developer/operator/investor in healthcare properties |
| Anchor Health Properties | Chairman | Oct 2015–Nov 2017 | Leadership through transition following sale to Brinkman |
| Anchor Health Properties | Chair Emeritus | Nov 2017–present | Continuing strategic involvement |
| The Rouse Company | Development Director | Eight years (dates not provided) | Responsible for development of urban retail projects |
| Villanova University (MBA program, Finance Dept.) | Adjunct Professor | 2018–2022 | Academic appointment in finance |
External Roles
| Organization | Role | Timing / Status | Notes |
|---|---|---|---|
| High Companies (Lancaster, PA) | Chair of the Board | Through Oct 2019 | Corporate board leadership |
| Women’s Way (Philadelphia) | Chair of the Board | Not specified | Not‑for‑profit organization |
| Kaiserman Company (Philadelphia) | Chair of the Board | As of Feb 2020 | Real estate company |
| The Ingerman Company (Collingswood, NJ) | Director | As of Oct 2022 | Board directorship |
Board Governance
- Committee assignments (effective Jan 1, 2025): Compensation Committee Chair; Audit Committee Member; Nominating & Corporate Governance Committee Member. All three committees comprised of independent directors under NYSE standards; Compensation Committee members also qualify as “non‑employee directors” under Rule 16b‑3 .
- Board/committee activity: Board held 13 meetings in 2024; no director attended fewer than 75% of the aggregate Board/committee meetings on which they served; all directors serving at the time attended the 2024 annual meeting .
- Committee meeting cadence in 2024: Audit (6), Compensation (6), Nominating & Corporate Governance (7), ESG (4) .
- Independence and financial expertise: The Board concluded Ms. Crowley is independent (SEC Rule 10A‑3 and NYSE) and her financial expertise qualifies her to serve on the Audit Committee .
- Compensation consultant: The Compensation Committee retained independent consultant Farient Advisors LLC to review programs and assist in developing 2024 annual and long‑term incentive plans .
Committee Roles Table
| Committee | Role | Notes |
|---|---|---|
| Compensation Committee | Chair (effective Jan 1, 2025) | Independent; authority to retain advisors and oversee all plans |
| Audit Committee | Member (effective Jan 1, 2025) | Independent; financial literacy; oversight of financial reporting and related‑party reviews |
| Nominating & Corporate Governance Committee | Member (effective Jan 1, 2025) | Independent; oversees Board composition and governance guidelines |
Fixed Compensation
2024 Director Compensation – Paula Crowley
| Component | Amount |
|---|---|
| Fees Earned or Paid in Cash ($) | $80,000 |
| Stock Awards ($) | $80,000 (time‑based LTIP Units) |
| Total ($) | $160,000 |
2024 Director Fee Schedule (Policy)
| Fee Type | Amount |
|---|---|
| Annual cash retainer (independent directors) | $55,000 |
| Lead Independent Director additional retainer | $25,000 |
| Audit Committee Chair | $20,000 |
| Audit Committee Member | $10,000 |
| Compensation Committee Chair | $15,000 |
| Compensation Committee Member | $7,500 |
| Nominating & Corporate Governance Committee Chair | $15,000 |
| Nominating & Corporate Governance Committee Member | $7,500 |
| ESG Committee Chair | $15,000 |
| ESG Committee Member | $7,500 |
For 2024, each independent director also received an annual equity‑based award valued at $80,000; the awards were time‑based LTIP Units .
Performance Compensation
- Equity instrument: Time‑based LTIP Units; generally vest on the first anniversary of the grant date; grant valued using the 10‑day VWAP .
- Options: Company’s equity plan had no stock options outstanding (weighted average exercise price N/A) as of Dec 31, 2024 .
2024 Director Equity Award – Paula Crowley
| Award Type | Grant Date | Valuation Price | Units | Grant‑Date Fair Value | Vesting |
|---|---|---|---|---|---|
| Time‑based LTIP Units | May 15, 2024 | $8.59 (10‑day VWAP) | 9,316 unvested LTIP Units as of Dec 31, 2024 | $80,000 | Generally vests on first anniversary of grant |
No performance metrics are attached to director equity (time‑based). Performance metrics cited in the proxy apply to executive incentive plans, not director compensation .
Other Directorships & Interlocks
| Company/Organization | Nature | Role | Notes |
|---|---|---|---|
| High Companies | Corporate | Chair of the Board (through Oct 2019) | External board leadership |
| Women’s Way | Not‑for‑profit | Chair of the Board | Non‑profit governance |
| Kaiserman Company | Corporate | Chair of the Board (as of Feb 2020) | Real estate focus |
| The Ingerman Company | Corporate | Director (as of Oct 2022) | Board directorship |
The proxy biography lists these roles; it does not state any current public company directorships for Ms. Crowley in the cited sections .
Expertise & Qualifications
- 40+ years of real estate experience; co‑founder and former CEO/Chair of Anchor Health Properties, a national healthcare real estate firm .
- Financial expertise sufficient for Audit Committee service; Board deems her independent under SEC Rule 10A‑3 and NYSE standards .
- Advanced education: Masters in City Planning (UPenn) and MBA (Wharton), BA (Middlebury) .
Equity Ownership
| Item | Detail |
|---|---|
| Beneficial ownership (shares) | 28,747; less than 1% (“*”) |
| Unvested LTIP Units (as of 12/31/2024) | 9,316 |
| Shares pledged as collateral | None; company states no shares beneficially owned by any executive officer, director or director nominee were pledged as of Feb 28, 2025 |
| Board Equity Ownership Policy | Each director must hold stock/LTIP Units equal to 3× annual cash retainer |
| Compliance with Ownership Policy | Company disclosed that since March 5, 2024 each director has met the policy |
| Hedging/Pledging | Hedging and pledging of company stock prohibited under company policies |
Governance Assessment
- Strengths:
- Independent director with relevant healthcare real estate operating and board leadership experience; Audit‑qualified .
- Elevated governance responsibilities as Compensation Committee Chair (effective 1/1/2025); committee employs an independent compensation consultant (Farient) .
- Strong alignment: mandatory equity component ($80k in LTIP Units), director ownership guideline (3× cash retainer) met by all directors, and prohibitions on hedging/pledging; no pledged shares reported .
- Adequate engagement: Board met 13 times in 2024; no director below 75% attendance; all attended annual meeting .
- Controls/Conflicts:
- Company has formal related‑person transaction review policies administered by Audit and Nominating & Corporate Governance Committees .
- A disclosed related‑party matter involved compensation of another director’s family member (Henry Cole’s son); both committees ratified and Mr. Cole abstained; no specific related‑party transactions involving Ms. Crowley are identified in the cited sections .
- RED FLAGS:
- None specific to Ms. Crowley disclosed in the cited sections (no pledging; equity is time‑based; independence affirmed) .
Note: Director compensation and governance details are based on GMRE’s 2025 DEF 14A (covering 2024 activity). Executive‑level provisions (e.g., clawback, performance metrics) are included for governance context but are not director‑specific unless stated .
Citations: